第一单位：
Institute of Biochemical Research of Barcelona (IIBB)-Spanish National Research Council (CSIC), Barcelona, Spain; Lipids and Cardiovascular Pathology Group, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
作者：
Aleyda,Benitez-Amaro [1]
;
Elena,Revuelta-López [2]
;
Olga,Bornachea [1]
;
Lídia,Cedó [3]
;
Àngela,Vea [4]
;
Laura,Herrero [5]
;
Nuria,Roglans [6]
;
Carolina,Soler-Botija [2]
;
David,de Gonzalo-Calvo [7]
;
Laura,Nasarre [4]
;
Sandra,Camino-López [4]
;
Eduardo,García [1]
;
Eugenia,Mato [8]
;
Francisco,Blanco-Vaca [9]
;
Antoni,Bayes-Genis [10]
;
David,Sebastian [11]
;
Joan Carles,Laguna [6]
;
Dolors,Serra [5]
;
Antonio,Zorzano [11]
;
Joan Carles,Escola-Gil [12]
;
Vicenta,Llorente-Cortes [13]
作者单位：
Institute of Biochemical Research of Barcelona (IIBB)-Spanish National Research Council (CSIC), Barcelona, Spain; Lipids and Cardiovascular Pathology Group, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
[1]
Heart Failure and Cardiac Regeneration (ICREC) Research Program, Health Sciences Research Institute Germans Trias i Pujol (IGTP), Badalona, Barcelona, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
[2]
Metabolic Basis of Cardiovascular Risk, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.
[3]
Institute of Biochemical Research of Barcelona (IIBB)-Spanish National Research Council (CSIC), Barcelona, Spain.
[4]
Department of Biochemistry and Physiology, School of Pharmacy, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, Spain; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
[5]
Department of Pharmacology, Toxicology and Therapeutic Chemistry, School of Pharmacy and Food Sciences, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, Spain.
[6]
Institute of Biochemical Research of Barcelona (IIBB)-Spanish National Research Council (CSIC), Barcelona, Spain; Lipids and Cardiovascular Pathology Group, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
[7]
CIBER Bioingeniería, Biomateriales y Nanomedicina, CIBER-BBN, Instituto de Salud Carlos III, Madrid, Spain.
[8]
Metabolic Basis of Cardiovascular Risk, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain; Departament de Bioquímica, Biología Molecular i Biomedicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
[9]
Heart Failure and Cardiac Regeneration (ICREC) Research Program, Health Sciences Research Institute Germans Trias i Pujol (IGTP), Badalona, Barcelona, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; Cardiology Service and Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain.
[10]
Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain; Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.
[11]
Metabolic Basis of Cardiovascular Risk, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: JEscola@santpau.cat.
[12]
Institute of Biochemical Research of Barcelona (IIBB)-Spanish National Research Council (CSIC), Barcelona, Spain; Lipids and Cardiovascular Pathology Group, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: vicenta.llorente@iibb.csic.es.
[13]
医学主题词
腺苷酸激酶(Adenylate Kinase);动物(Animals);心钠素(Atrial Natriuretic Factor);细胞, 培养的(Cells, Cultured);葡糖耐受不良(Glucose Intolerance);胰岛素抗药性(Insulin Resistance);脂类代谢(Lipid Metabolism);男(雄)性(Male);小鼠(Mice);小鼠, 近交C57BL(Mice, Inbred C57BL);小鼠, 肥胖(Mice, Obese);小鼠, 转基因(Mice, Transgenic);肌细胞, 心脏(Myocytes, Cardiac);肥胖症(Obesity)
DOI
10.1016/j.metabol.2020.154191
PMID
32112822
发布时间
2020-07-06
换一批
